Zacks Research Has Bullish Forecast for Avantor Q2 Earnings

Avantor, Inc. (NYSE:AVTR) – Zacks Research lifted their Q2 2026 earnings per share estimates for shares of Avantor in a research report issued to clients and investors on Tuesday, December 10th. Zacks Research analyst D. Dey now forecasts that the company will post earnings of $0.29 per share for the quarter, up from their prior estimate of $0.28. The consensus estimate for Avantor’s current full-year earnings is $0.98 per share.

Several other equities research analysts also recently commented on AVTR. Barclays reduced their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. UBS Group decreased their target price on Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, October 8th. Wells Fargo & Company cut their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, October 28th. Robert W. Baird lowered their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $34.00 price target on shares of Avantor in a research report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $27.69.

Avantor Stock Performance

NYSE:AVTR opened at $22.33 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. The firm has a market cap of $15.20 billion, a price-to-earnings ratio of 48.98, a price-to-earnings-growth ratio of 2.75 and a beta of 1.29. Avantor has a twelve month low of $19.59 and a twelve month high of $28.00. The company has a 50-day moving average of $22.53 and a 200-day moving average of $23.54.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. boosted its holdings in Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after purchasing an additional 1,391 shares during the period. UMB Bank n.a. bought a new stake in shares of Avantor during the third quarter worth $49,000. Nisa Investment Advisors LLC boosted its holdings in shares of Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock valued at $53,000 after acquiring an additional 835 shares in the last quarter. GAMMA Investing LLC increased its holdings in Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after purchasing an additional 1,285 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its holdings in shares of Avantor by 278.0% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock worth $130,000 after purchasing an additional 3,700 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.